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at maximum tolerated doses are ineffec
tive in combating cancer. In a preclini
cal study of interferon, Dr. Fidler found
that the optimal biologic dose-the
drug level at which the surrogate
markers of disease were lowest-was
only one tenth the maximum tolerated
dose. "As you increase the dose toward
tolerance, the markers become elevated
because the cells no longer respond to
interferon," he said.
In fact, the cells reach a state of
tolerance that destroys the very signaling
cascade on which the efficacy of these
drugs depends. Because the relationship
between dosage and efficacy is nonlinear
and because these agents are, at least in
the short term, nontoxic, future trials
should attempt to identify the optimal
biologic doses rather than the maximum
tolerated doses.
Mose antiangiogenic agents are still
in the early stages of clinical assessment,
but the results so far suggest that these
drugs cause disease stabilization, rather
than regression, in humans. A reduction
in the time to disease progression has
been an important finding, since it
proves that the drugs render tumor cells
incapable of growth. Nevertheless, it is
somewhat disappointing that patients
did not show the marked tumor shrink
age seen earlier in laboratory mice.
"We have to lower our goals in cancer
treatment," said Lee Ellis, M.D., an

Dr. Roy Herbst, right, an assistant professor in the Department of Thoracic/Head and
Neck Medical Oncology, examines patient
with the help of Mercedes
Guerra, an advanced practice nurse. Dr. Herbst is the principal investigawr of several
trials of antiangiogenic agents, most notably endostatin.
associate professor in the Department
of Surgical Oncology. "We need to
slow growth of tumors to a point where
patients can live with their disease as
a chronic condition."
By slowing or stopping tumor growth
and metastasis, angiogenesis inhibitors
could provide the fLrst "maintenance
therapy" for solid tumors. Angiogenesis
inhibitors might also prove effective in
preventing disease in patients at high
risk for various malignancies. In addi-

tion, they might be useful in early-stage
cancers to prevent disease recurrence
among patients who have undergone
surgical resection of the primary tumor.
Eventually, clinicians hope to combine
antiangiogenic agents with chemo
therapy to stave off tumor progression.
Researchers have also begun to explore
the synergism between antiangiogenic
agents in the laboratory. When adminis
tered co mice, the combination of

(Continued on page 4)

PROTOCOLS

•

•
•

cancer following treatment with
interleukin-2 (1099-291). Physician:
Christopher J. Logothetis, M.D.
Multicenter, open-ended, doubleblind, placebo-controlled phase Ill
study of AE-941 in addition to
combined-modality treatment (chemotherapy and radiation therapy) for
locally advanced unresectable nonsmall cell lung cancer (1099-303).
Physician: Charles Lu, M.D.
Phase I trial of thalidomide for
multiple myeloma (DM98-359).
Physician: Donna M. Weber, M.D.
A phase I dose-escalation and
pharmacokinetic evaluation of oral
LY317615 in patients with advanced
cancer (ID00-382). Physician: Roy
Herbst, M.D., Ph.D.

• A tolerance and efficacy trial of

•
•

preoperative thalidomide treatment
followed by radical retropubic prostatectomy in select patients with
locally advanced prostate cancer
(1000-089). Physician: Danai Daliani,
M.D.

A phase II trial of thalidomidedexamethasone for multiple myeloma
(ID00-070). Physician: Donna M.
Weber,M.D.
Phase II study of gemcitabine-based
chemoradiation and TNP-470 for
patients with locally advanced,
nonmetastatic adenocarcinoma of
the pancreas (ID98-248). Physician:
Douglas 8. Evans, M.D.

• Phase 1/11 study of paclitaxel,

estramustine phosphate, and
thalidomide for patients with meta-

static androgen-independent prostate
carcinoma (ID00-087). Physician:
Danai Daliani, M.D.
• A phase I, single-center, open-label,
dose-escal ation, safety, and pharma
cokinetic study of recombinant
human endostatin administered by
continuous intravenous infusion to
patients with cancer (1001-074).
Physician: Roy Herbst, M.D., Ph.D.•
FoA MORE INFORMATION about these clinical
trials, physicians or patients may call the
M. D. Anderson lnfatmation Line. Those
within the United States should call (800)
392-1611; those in Houston or outside the
United States should call (713) 792-6161.
Visit the M. D. Anderson Cancer
Center clinical trials Web site at httf)://
www.cUnicaltrials. org for a broader listing
of treatment research protocols.
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rs Prevention of
Patients with Cancer
menopause are at increased risk of
developing osteoporosis. According to
the National Osteoporosis Foundation
(NOF), women often lose up to 20%
of their bone mass in the five to seven
years after menopause, and for some
women with breast cancer, this loss of
bone mass can begin up to 10 years
earlier than normal. Furthermore,
chemotherapy and radiation therapy
(not necessarily associated with breast
and prostate cancers) can cause gonadal
damage, which may also cause a loss of
estrogen or testosterone.
"Since estrogen or testosterone
deficiency leads to bone loss," said Dr.
Sellin, "prompt and careful replacement
is important for these patients."
Hormone-replacement therapy with
estrogen, estrogen and progestin, or
testosterone can be used to prevent and
treat osteoporosis in many of these
individuals, although estrogen-replace
ment therapy is contraindicated in
patients with breast cancer. For those
patients, other drugs are avail
able, such as raloxifene (Evista),
a selective estrogen receptor
modulator approved by the Food
and Drug Administration (FDA)
to both prevent and treat osteo
porosis. Similarly, tamoxifen,
which is often used as adjuvant
therapy after breast cancer, has
also been found to protect
against bone loss in postrneno
pausal women.
Another FDA-approved
drug for preventing and treating
osteoporosis is alendronate
------:
(Fosamax), a bisphosphonate,
or agent that inhibits bone
resorption at sites of osteoid
mineralization. According to
the NOF, this drug is often
indicated specifically for the
treatment of steroid-induced
osteoporosis. Calcitonin
(Miacalcin), a naturally occur
ring hormone that is important
Dr. Rena Sellin, left, a professor in the Depart
for calcium regulation and bone
metabolism, has also been
ment of Endocrine Neoplasia and Hormonal
approved in the form of a nasal
Disorders, discusses osteoporosis prevention with
a patient in rhe clinic.
spray to creat osteoporosis,

bone resorption. For instance, long-term
use of such glucocorticoids as pred
nisone and cortisone, which are often
used to treat patients with leukemias
and lymphomas, can cause even further
bone loss.
Steroids, along with cranial irradia
tion, can also cause growth hormone
deficiencies. According to Dr. Sellin,
most bone development occurs by the
age of 25, so once many survivors of
childhood cancers reach adulthood,
they are at increased risk for osteo,
porosis, not because their bones have
deteriorated but because they have
not accumulated normal bone masses.
Another group of at-risk patients are
those treated for hormone-responsive
cancers. Prostate cancer, for example,
is commonly treated with orchiectomy
(excision of one or both of the testes) or
with the antineoplastic agent leuprolide
(Lupron), both of which cause androgen
ablation or deficiency. Similarly, women
with breast cancer who develop early

"Since estrogen or
testosterone deficiency
leads to bone loss, prompt
and careful replacement
is important."
- Rena Sellin, M.D., professor,
Department of Endocrine
Neoplasia and Hormonal Disorders
mainly in postmenopausal women.
According to Dr. Sellin, all of these
agents work by inhibiting the activity of
osteoclasts. While many of them have
also been shown to increase bone
density, they work primarily by inhibit
ing bone resorption so that normal bone
formation can occur more quickly.
"For the most part, agents that are
used in patients with cancer to treat
osteoporosis are similar to the agents
that are used in other patients," said
Dr. Sellin. The biggest difference is
that patients with cancer have certain
contraindications that limit the number
of drugs they can choose from.
Aside from medications, a healthy
lifestyle can be the biggest key to
preventing osteoporosis and the hip,
spine, and wrist fractures commonly
associated with reduced bone mass.
Quitting smoking, increasing calcium
intake, limiting alcohol consumption,
treating metabolic and endocrine
disorders, and exercising can all contrib
ute. While weight-bearing exercises
have been shown to improve muscle
mass (which protects bones), in many
instances they also result in fractures
in individuals whose bones are already
weak. According to Dr. Sellin, a healthy
alternative is to exercise in the water.
"Exercising in water allows patients
who have feeble skeletons to stretch and
increase muscle tone and muscle mass
without putting their bones at risk,"
Dr. Sellin said.
Beyond that, Dr. Sellin advises
patients to use common sense in their
daily activities, including wearing shoes
with nonslip soles and abstaining from
activities that could increase the risk
of falling.•
FOR MORE INFORMATION,

contaet

Dr. Sellin at (713) 792�2841.
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